SCHEMBL5584525

SCHEMBL5584525

CCOC(=O)/C=C/c1ccccc1OCOC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.52
ALDH1A1 P00352 6/20 0.52
HPGD P15428 5/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
MAPT P10636 4/20 0.49
LMNA P02545 3/20 0.49
ATM Q13315 1/20 0.49
FDPS P14324 1/20 0.49
NFE2L2 Q16236 2/20 0.49
TFEB P19484 1/20 0.48
KMT2A Q03164 3/20 0.47
NPC1 O15118 1/20 0.47
S1PR4 O95977 1/20 0.47
ITGA4 P13612 1/20 0.47
S1PR1 P21453 1/20 0.47
MAPK1 P28482 1/20 0.47
RAB9A P51151 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TLR9 Q9NR96 1/20 0.47
MEN1 O00255 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5584526 1.00 KDM4E (0.52) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL3536949 0.88 SMN1; SMN2 (0.60) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL3536947 0.88 SMN1; SMN2 (0.60) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL14143273 0.87 NFE2L2 (0.54) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL14501345 0.87 NFE2L2 (0.54) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL9419131 0.86 ALDH1A1 (0.42) KDM4EALDH1A1HPGDSMN1; SMN2FDPS
SCHEMBL9419133 0.86 ALDH1A1 (0.42) KDM4EALDH1A1HPGDSMN1; SMN2FDPS
SCHEMBL7221481 0.86 ALDH1A1 (0.54) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL7221477 0.86 ALDH1A1 (0.54) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL15188 0.85 KDM4E (0.67) KDM4EALDH1A1HPGDSMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989430-B2 Antibacterial agents REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2011-08-02 US disclosed
US-7989430-B2 Antibacterial agents REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2011-08-02 US disclosed
US-20080293666-A1 Antibacterial Agents REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2008-11-27 US disclosed
US-20080293666-A1 Antibacterial Agents REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2008-11-27 US disclosed
WO-2007067559-A2 ANTIBACTERIAL AGENTS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2007-06-14 WO disclosed
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
EP-1188747-B1 PHENOXYPROPYLAMINE COMPOUNDS MITSUBISHI PHARMA CORP (JP) 2005-09-07 EP disclosed
US-20040138227-A1 Phenoxypropylamine compounds NISHIYAMA AKIRA 2004-07-15 US disclosed
US-6720320-B2 ANTISEROTONINE AGENTS MITSUBISHI PHARMA CORPORATION (JP) 2004-04-13 US disclosed
US-20020111358-A1 Phenoxypropylamine compounds MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 US disclosed
EP-1188747-A1 PHENOXYPROPYLAMINE COMPOUNDS Mitsubishi Pharma Corporation (JP) 2002-03-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138227-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A KDM4E 610/4885ALDH1A1 443/4885HPGD 2703/4885
US-20080293666-A1 Antibacterial Agents MRPL21, ABCB7, MSR1 KDM4E 3925/4885ALDH1A1 1972/4885HPGD 2789/4885
US-20020111358-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A KDM4E 610/4885ALDH1A1 443/4885HPGD 2703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.